American College of Cardiology

FUSTER ET AL., ACC/AHA/ESC GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH ATRIAL FIBRILLATION
J Am Coll Cardiol 2001;38:1266i-1xx

ACC/AHA/ESC Guidelines for the Management of Patients with Atrial Fibrillation

Figures & Tables

Figure 1. Standard 12-lead surface electrocardiogram showing atrial fibrillation with a controlled rate of ventricular response.

Figure 2. Standard 12-lead surface electrocardiogram showing typical atrial flutter with variable atrioventricular conduction.

Figure 3. Patterns of atrial fibrillation.

Figure 4. Prevalence of AF in 2 American epidemiological studies.

Figure 5. Estimated prevalence of AF in relation to age in the United States, based on 4 population-based surveys.

Figure 6. Incidence of atrial fibrillation in 2 American epidemiological studies.

Figure 7. Relative risk of stroke and mortality in patients with AF compared with patients without AF.

Figure 8. Principal electrophysiological mechanisms of atrial fibrillation.

Figure 9. Pharmacological management of patients with newly discovered atrial fibrillation.

Figure 10. Pharmacological management of patients with recurrent paroxysmal atrial fibrillation.

Figure 11. Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation.

Figure 12. Pharmacological management of patients with recurrent persistent or permanent atrial fibrillation.

Figure 13. Arrhythmia-free survival after electrical cardioversion in patients with persistent atrial fibrillation.

Figure 14. Hypothetical illustration of cardioversion failure.

Figure 15. Stroke rates in relation to age among patients with atrial fibrillation in the Framingham Heart Study.

Figure 16. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular AF: adjusted-dose warfarin compared with placebo.

Figure 17. Adjusted odds ratios for ischemic stroke and intracranial bleeding in relation to intensity of anticoagulation in randomized trials of antithrombotic therapy for patients with atrial fibrillation.

Figure 18. Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular AF: warfarin compared with aspirin and aspirin compared with placebo.

Table 1. Prevalence of Atrial Fibrillation in Patients With Heart Failure.

Table 2. Anatomic and Electrophysiological Factors Promoting the Initiation and/or Maintenance of AF.

Table 3. Demographics and Associated Conditions Among Patients With Atrial Fibrillation in the ALFA Study.

Table 4. Minimum and Additional Clinical Evaluation in Patients With Atrial Fibrillation.

Table 5. Objectives of Rhythm Control in Patients With Atrial Fibrillation.

Table 6. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of Less Than or Equal to 7 Days' Duration.

Table 7. Recommendations for Pharmacological Cardioversion of Atrial Fibrillation of More Than 7 Days' Duration.

Table 8. Recommended Doses of Drugs Proven Effective for Pharmacological Cardioversion of Atrial Fibrillation.

Table 9. Vaughan Williams Classification of Antiarrhythmic Drug Actions.

Table 10. Typical Doses of Drugs Used to Maintain Sinus Rhythm in Patients With Atrial Fibrillation.

Table 11. Types of Proarrhythmia During Treatment With Various Antiarrhythmic Drugs for Atrial Fibrillation or Atrial Flutter According to the Vaughan Williams Classification.

Table 12. Factors Predisposing to Drug-Induced Ventricular Proarrhythmia.

Table 13. Pharmacological Treatment Before Cardioversion in Patients With Persistent Atrial Fibrillation: Effects of Various Antiarrhythmic Drugs on Acute and Subacute Outcome of Transthoracic Direct Current Shock.

Table 14. Intravenous Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation.

Table 15. Orally Administered Pharmacological Agents for Heart Rate Control in Patients With Atrial Fibrillation.

Table 16. Summary of Recommendations for Use of Pharmacological Agents to Control the Rate of Ventricular Response to Atrial Fibrillation.

Table 17. Risk Factors for Ischemic Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation.

Table 18. Published Risk-Stratification Schemes for Primary Prevention of Thromboembolism in Patients With Nonvalvular Atrial Fibrillation.

Table 19. Risk-Based Approach to Antithrombotic Therapy in Patients With Atrial Fibrillation.

Table 20. Randomized Trials of Antithrombotic Therapy in Patients With Nonvalvular Atrial Fibrillation.

Table 21. Multivariate Predictors of Postoperative Atrial Arrhythmias in Patients Undergoing Myocardial Revascularization Surgery.

Copyright © 2001 by the American College of Cardiology, American Heart Association, Inc., and the European society of Cardiology
Published by Elsevier Science Inc.